1H-Indole-3-acetamide, 6-chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-α-oxo-
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain. | Journal of clinical pharmacology 20120501 |
| A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. | The Journal of rheumatology 20110501 |
| Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. | Journal of medicinal chemistry 20100325 |
| Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles. | Bioorganic & medicinal chemistry letters 20100201 |
| Displacement assay for the detection of stabilizers of inactive kinase conformations. | Journal of medicinal chemistry 20100114 |
| Inhibition of p38: has the fat lady sung? | Arthritis and rheumatism 20090201 |
| Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. | Cancer research 20070515 |
| American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA. | IDrugs : the investigational drugs journal 20070201 |
| Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. | Blood 20061215 |
| Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. | Cancer research 20060701 |
| Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. | Experimental cell research 20060610 |
| Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. | Leukemia 20060601 |
| Developmental therapeutics for myelodysplastic syndromes. | Journal of the National Comprehensive Cancer Network : JNCCN 20060101 |
| New agents in the treatment of MDS. | Clinical advances in hematology & oncology : H&O 20051101 |
| p38 MAP kinase inhibitors: many are made, but few are chosen. | Current opinion in drug discovery & development 20050701 |